1. Home
  2. / Industry
  3. / U.S.-China Dispute Reaches Pharmaceutical Industry: Global Conflict Could Cause Drug Prices to Surge, Doubling Costs in Brazil and Impacting Millions Worldwide!
Reading time 3 min of reading Comments 0 comments

U.S.-China Dispute Reaches Pharmaceutical Industry: Global Conflict Could Cause Drug Prices to Surge, Doubling Costs in Brazil and Impacting Millions Worldwide!

Written by Valdemar Medeiros
Published on 09/11/2024 at 09:20
Disputa entre EUA e China alcança a indústria farmacêutica
Foto: Dall-e
Seja o primeiro a reagir!
Reagir ao artigo

The Dispute Between The US And China Intensifies And Reaches The Pharmaceutical Industry, With Companies Breaking Strategic Partnerships. This Conflict May Directly Impact Consumers, Leading To An Increase In Drug Prices And Affecting The Global Supply Chain.

Dispute Between The US And China: US Pharmaceutical And Biotechnology Companies Have Come To Rely On Chinese Partners For Production, Research, And Ingredients. Now, With Increasing Geopolitical Tensions, Some Are Looking For Alternatives, Leading To Higher Drug Prices In The US And China.

Understand The Dispute Between The US And China In The Pharmaceutical Industry

From Major Pharmaceutical Companies Like AstraZeneca To Smaller Biotechnology Firms Like Amicus Therapeutics From New Jersey, Which Is Seeking A Non-Chinese Partnership For The Supply Of Raw Materials For Its Rare Disease Treatment, Companies Say It’s Time To Reduce The Risk Of China.

Industry Officials State That One Consequence Of The US-China Dispute Is The Delay In Drug Launches And Increased Drug Prices In The US, As The Transition Requires Time And Money.

Basically Without The Knowledge Of American Patients, US And European Companies Often Depend On China For Chemical Services And Basic Pharmaceutical Ingredients, And That’s Why The US-China Disputes Over Trade And Military Issues In Recent Years Have Shaken The Industry. Executives State That The Cost Of High-Level Chinese Labor Is Typically Lower Than In The West.

According To Nello Mainolfi, CEO Of Kymera Therapeutics, Now Companies Are Making Choices Focused On Reducing The Risks Of Depending On A Single Country, Even If It Leads To Higher Drug Prices. His Company, Based In Massachusetts And Developing Drugs For Cancer And Immune System Disorders, Relies On Chinese Companies For Production And Manufacturing, However, It Has Started To Do More Of That Work In Europe, India, And The US.

New Law For The US And China Pharmaceutical Industry

An Incentive That Could Impact The Rise In Drug Prices Is The Biosafety Law, Which Was Passed In The House In September With Overwhelming Bipartisan Support. The Legislation Prevents Companies Receiving Government Funds Or Contracts From Doing Business With A List Of Problematic Chinese Companies.

The Biggest Names On The List Are WuXi AppTec And WuXi Biologics, Two Chinese Affiliate Companies That Thousands Of Clients Worldwide Have Turned To For Research And Manufacturing.

WuXi AppTec Stated In May That The Inclusion Of Its Name In The Bill Is “A Preventive And Unjustified Designation, Without Due Process.”

Both It And WuXi Biologics Have Claimed They Do Not Pose A Security Risk To The US Or Any Other Country. The Prospects For The Biosafety Law In The Senate Are Uncertain This Year, And The Current Version Gives Companies Until 2032 To Cut Ties With Chinese Firms.

The US And China Can Still Maintain Relations

Even With The Possible Increase In Drug Prices, The Changes Do Not Mean A Complete Break In Industrial Ties Between China And The West. American And European Pharmas Still Want To Sell Their Products In China, The Second-Largest Drug Market After The US And A Country With A Rapidly Aging Population. 

Chinese Biotechnology Companies Have Signed Billions Of Dollars In Licensing Deals Aiming To Bring Local Drugs To The World.

The Biggest Impact Is On The Drug Supply Chains. One Example Of An American Company That Cut Its Ties With China Is Vir Biotechnology, Based In San Francisco, Which Develops Antiviral And Cancer Treatments.

Inscreva-se
Notificar de
guest
0 Comentários
Mais recente
Mais antigos Mais votado
Feedbacks
Visualizar todos comentários
Valdemar Medeiros

Formado em Jornalismo e Marketing, é autor de mais de 20 mil artigos que já alcançaram milhões de leitores no Brasil e no exterior. Já escreveu para marcas e veículos como 99, Natura, O Boticário, CPG – Click Petróleo e Gás, Agência Raccon e outros. Especialista em Indústria Automotiva, Tecnologia, Carreiras (empregabilidade e cursos), Economia e outros temas. Contato e sugestões de pauta: valdemarmedeiros4@gmail.com. Não aceitamos currículos!

Share in apps
0
Adoraríamos sua opnião sobre esse assunto, comente!x